Zhou Y, Husman T, Cen X, Tsao T, Brown J, Bajpai A
Int J Mol Sci. 2022; 23(13).
PMID: 35806311
PMC: 9266896.
DOI: 10.3390/ijms23137311.
Racca F, Pellegatta G, Cataldo G, Vespa E, Carlani E, Pelaia C
Front Physiol. 2022; 12:815842.
PMID: 35095572
PMC: 8790151.
DOI: 10.3389/fphys.2021.815842.
He Y, Yu Y, Li Y, Duan W, Sun Z, Yang J
Front Neurosci. 2021; 14:582279.
PMID: 33613171
PMC: 7887313.
DOI: 10.3389/fnins.2020.582279.
Surbek M, Tse W, Moriggl R, Han X
Cytokine. 2021; 139:155392.
PMID: 33482575
PMC: 8276772.
DOI: 10.1016/j.cyto.2020.155392.
Lin S, Huang G, Xiao Y, Sun W, Jiang Y, Deng Q
Front Immunol. 2017; 8:1713.
PMID: 29255466
PMC: 5722806.
DOI: 10.3389/fimmu.2017.01713.
The clinical significance and impact of interleukin 15 on keratinocyte cell growth and migration.
Jones A, Griffiths J, Sanders A, Owen S, Ruge F, Harding K
Int J Mol Med. 2016; 38(3):679-86.
PMID: 27460304
PMC: 4990290.
DOI: 10.3892/ijmm.2016.2687.
IL-15 Superagonist Expands mCD8+ T, NK and NKT Cells after Burn Injury but Fails to Improve Outcome during Burn Wound Infection.
Patil N, Luan L, Bohannon J, Guo Y, Hernandez A, Fensterheim B
PLoS One. 2016; 11(2):e0148452.
PMID: 26859674
PMC: 4747596.
DOI: 10.1371/journal.pone.0148452.
Trans-presentation of interleukin-15 by interleukin-15 receptor alpha is dispensable for the pathogenesis of autoimmune type 1 diabetes.
Bobbala D, Mayhue M, Menendez A, Ilangumaran S, Ramanathan S
Cell Mol Immunol. 2016; 14(7):590-596.
PMID: 26853723
PMC: 5520411.
DOI: 10.1038/cmi.2015.102.
The Immunologic Mechanisms of Eosinophilic Esophagitis.
Hill D, Spergel J
Curr Allergy Asthma Rep. 2016; 16(2):9.
PMID: 26758862
PMC: 4913464.
DOI: 10.1007/s11882-015-0592-3.
Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.
Gotlib J
Curr Hematol Malig Rep. 2015; 10(4):351-61.
PMID: 26404639
DOI: 10.1007/s11899-015-0280-3.
Targeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member cytokines with selectable target spectrum.
Nata T, Basheer A, Cocchi F, Van Besien R, Massoud R, Jacobson S
J Biol Chem. 2015; 290(37):22338-51.
PMID: 26183780
PMC: 4566211.
DOI: 10.1074/jbc.M115.661074.
The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy.
Waldmann T
Cancer Immunol Res. 2015; 3(3):219-27.
PMID: 25736261
PMC: 4351780.
DOI: 10.1158/2326-6066.CIR-15-0009.
Interleukin-15 in the treatment of cancer.
Waldmann T
Expert Rev Clin Immunol. 2014; 10(12):1689-701.
PMID: 25359408
PMC: 7701979.
DOI: 10.1586/1744666X.2014.973856.
Molecular pathways: interleukin-15 signaling in health and in cancer.
Mishra A, Sullivan L, Caligiuri M
Clin Cancer Res. 2014; 20(8):2044-50.
PMID: 24737791
PMC: 3989546.
DOI: 10.1158/1078-0432.CCR-12-3603.
Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia.
Chen J, Petrus M, Bamford R, Shih J, Morris J, Janik J
Blood. 2011; 119(1):137-43.
PMID: 22049515
PMC: 3251226.
DOI: 10.1182/blood-2011-04-346759.
Interleukin-15 biology and its therapeutic implications in cancer.
Steel J, Waldmann T, Morris J
Trends Pharmacol Sci. 2011; 33(1):35-41.
PMID: 22032984
PMC: 3327885.
DOI: 10.1016/j.tips.2011.09.004.
The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases.
Gabay C, McInnes I
Arthritis Res Ther. 2009; 11(3):230.
PMID: 19519923
PMC: 2714102.
DOI: 10.1186/ar2680.
Low dose IL-15 induces snap arming of CD44(low) T lymphocytes in the absence of antigen.
Tamang D, Alves B, Elliott V, Fraser S, Redelman D, Hudig D
Cell Immunol. 2008; 251(2):93-101.
PMID: 18485336
PMC: 2613908.
DOI: 10.1016/j.cellimm.2008.04.007.
Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal.
Tamang D, Redelman D, Alves B, Vollger L, Bethley C, Hudig D
Cytokine. 2006; 36(3-4):148-59.
PMID: 17188506
PMC: 1850105.
DOI: 10.1016/j.cyto.2006.11.008.
Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation.
Ugen K, Kutzler M, Marrero B, Westover J, Coppola D, Weiner D
Cancer Gene Ther. 2006; 13(10):969-74.
PMID: 16763607
PMC: 3277848.
DOI: 10.1038/sj.cgt.7700973.